Introduction
The 'two-hit' hypothesis (Knudson, 2001 ) has dominated cancer genetics for over 20 years. In this model, one copy of a tumour suppressor gene (TSG) is inactivated by a nonsense or frameshift mutation, and the other copy is inactivated by a similar mutation or by loss of heterozygosity (LOH). Although rarely stated explicitly, the 'two-hit' model implicitly applies to a diploid cell. In contrast, the typical cancer cell has become polyploid. Thus, two questions are unanswered. First, do TSGs require three, four or more hits if they need to be inactivated in a polyploid cancer cell, or is this so unlikely that TSG inactivation is uncommon in such a situation? The failure to find many commonly mutated TSGs in colorectal cancer (CRC) or breast cancer suggests that the latter might be correct (Wood et al., 2007) . Second, for those TSGs that are inactivated before the tumour cell becomes polyploid, does acquisition of a near-triploid or near-tetraploid state simply leads to random gain of one or both copies of the mutant TSG with no functional consequences? This study addresses this latter question.
Bi-allelic APC mutations are generally believed to initiate colorectal tumorigenesis. Although there is debate as to whether APC mutations might occur on a background of genetic instability (Michor et al., 2005) or, indeed, cause instability (Fodde and Smits, 2001) , most evidence indicates that APC is mutated when cells are near-diploid rather than grossly aneuploid. We have shown previously that the APC TSG does not acquire mutations that lead to simple protein inactivation. The bi-allelic APC mutations within colorectal tumours are distributed non-randomly within the gene (Lamlum et al., 1999) , with the position and type of the second hit depending on the random first hit (Figure 1 ). The observed APC mutations are probably selected because they lead to an optimal level of Wnt signalling (Lamlum et al., 1999; Albuquerque et al., 2002) . Critical determinants of the positions of APC mutations appear to be their locations relative to the protein's seven 20-amino acid repeats (20AARs) that take part in b-catenin binding and degradation.
Given these selective constraints on APC mutations, we reasoned that the process of tumour progression might take the colorectal tumour cell away from its optimal level of Wnt signalling. The optimal Wnt signalling of a late CRC might, for example, be very different from that of an early adenoma. One reason might be that the tumour cell's microenvironment has changed, or that additional genetic changes-such as a polyploid karyotype-have been acquired. Thus, although a near-diploid colorectal tumour cell might typically harbour one APC mutation leaving no 20AARs and another leaving two 20AARs, a triploid carcinoma cell would end up with a total of either two 20AARs or four 20AARs, depending on which copy of chromosome 5 was gained when polyploidy was acquired. It is entirely possible that neither of these genotypes is the optimum for that cell. We wondered, therefore, whether the 'two-hit' hypothesis required amendment in the typical CRC, in that the APC gene might sometimes acquire additional mutations during tumour progression that returned the cell closer to its optimum Wnt level. We therefore tested the idea that third hits occur at APC in CRCs, by studying both cell lines and primary tumours.
Results
Models of mutation, LOH and copy number change at APC For a TSG, the observed pattern of truncating mutations, LOH and copy number change usually allow the underlying order and types of changes to be deduced, although this is easier in cell lines than in primary cancers. Figure 1 shows how multiple hits at the APC locus would be reflected in observed genetic data. Initially, two hits occur in a diploid cell. The cell then becomes polyploid, resulting in trisomy, through some unspecified mechanism. Third hits, if we discount polyploidization as a hit, are then presumed to occur.
Consider first the most common scenario, in which two truncating mutations are the initial hits at APC. When near-triploidy occurs, one of the two chromosome 5 homologues is duplicated. A third hit might then occur by the deletion of one copy of APC. If this affects the chromosome 5 that has not been duplicated in the transition to polyploidy, there will be LOH of that deleted region (Figure 1(1A) ). If the other (duplicated) chromosome 5 is deleted, there is no LOH (Figure  1(1B) ). If there is gain of APC, that change is readily detectable, but there is no LOH (Figure 1(1C) ).
In the second scenario, there occurs at the neardiploid stage a truncating mutation accompanied by a second hit deletion, and hence LOH results. When triploidy occurs, duplication of one homologue leads to LOH with a two-copy deletion (Figure 1(2A) ) or LOH with a single-copy deletion (Figure 1(2B) ), depending on the homologue that is duplicated. The regions of deletion and LOH coincide (that is, their boundaries are identical). There is no true third hit in these scenarios. However, a third hit-for example, in the form of a further copy number change-could occur and would be detectable by array comparative genomic hybridization (aCGH) if it affected a region different from that affected by the second-hit deletion (see below for an example in a primary CRC, no. 622).
In scenario three, the second hit is copy-neutral LOH (mitotic recombination, gene conversion or chromosomal non-disjunction and reduplication). Triploidy leads to three essentially identical copies of a region of variable size around APC. A third hit in the form of copy number deletion (Figure 1(3A) ) will usually be detectable, and distinguishable from scenario 2 of Figure 1 because the region is unlikely to match perfectly the region of LOH. Third hit by copy number gain is readily detectable (Figure 1(3B) ). Also, third hits might take the form of additional truncating mutations, presumably 5 0 of the existing mutation (Figure 1(3C) ). Such protein-truncating third hits might also occur in scenarios 1 and 2, but are omitted from Figure 1 for the sake of simplicity.
Other genetic pathways involving multiple hits at APC might occur. Those shown have been chosen because they tend to correspond to the observed data (see below). Some third hits, moreover, might be cryptic. For example, scenarios 1A and 2B of Figure 1 result in the same observed data, whereas one has involved a third hit and the other has not. Other cryptic third hits might occur-for example, in scenario 3A of Figure 1 if the region of deletion is the same as that of the original copy-neutral LOH. In other cases, gains and deletions at APC might overlap, causing complex patterns that are difficult to decipher. In the analysis below, we score the presence of third hits conservatively, but use Figure 1 as a framework for our interpretation.
Three hits at APC are frequent in CRC cell lines Comprehensive screening for large-and small-scale mutations and for true LOH has rarely been undertaken in CRCs at the APC locus. We initially screened a set of 47 CRC cell lines. Overall, 38 (81%) of the cell lines harboured one or more nonsense or frameshift APC mutations. Two protein-truncating mutations were found in 14 (30%) of the cell lines. LOH was a common event, occurring in 18 (38%) cell lines. Most LOH was copy neutral, resulting from whole-chromosome loss/ regain in 4 cases and mitotic recombination, with a break point between 67 Mb and APC, in 10 cases. An additional four cell lines had LOH by deletion.
In at least 13 of 47 (28%) of the CRC cell lines, the genetic changes at APC could not readily be explained by only two hits (Table 1, Figure 1 ). In the near-triploid lines LS123, SW948 and C75, two truncating APC mutations were accompanied by a deletion of one copy of the gene, but no LOH (Figure 1(1B) ); a similar mechanism almost certainly applied to COLO205. In SW837, LS411, NCI-H747 and C106 cell lines, there were two truncating APC mutations together with gain of one gene copy (Figure 1(1C) ). The same sequence of mutations had almost certainly occurred in PC/JW, SW1116 and C32; in these cell lines, there was only one detected truncating mutation, but as the gains flanked APC by at least several megabases and were extremely unlikely to inactivate APC, the most plausible explanation was that these lines had a cryptic, proteintruncating second hit, with the gain as a third hit. In all of these 11 CRC cell lines, the most parsimonious sequence of events (see detailed explanation in Figure 1 ) was that the truncating mutation(s) and/or LOH were the initiating two hits at APC in a cell disomic for chromosome 5, and that the copy number change occurred subsequently during tumorigenesis.
Four cell lines (C99, GP5D, C125 and SW1417) had acquired one truncating mutation and an interstitial deletion of one copy of APC, the position of the deletion matching a region of LOH. The underlying order and number of mutations were uncertain in these lines. The most likely scenarios were that a deletion was the second hit in a diploid cell, causing LOH (Figure 1(2) ), or that a third-hit deletion had occurred (Figure 1(1A) ), after each chromosome had initially acquired two truncating mutations.
There was no simple tendency for cell lines to end up with a particular total number of 20AARs in their mutant proteins (details not shown). However, the position/types of the APC mutations were associated with the presence of third hits. After excluding the C99, GP5D, C125 and SW1417 cell lines from the analysis (owing to the uncertainty regarding the order and number of hits in these cases), third hits were found in only 2 of 14 (14%) cell lines with a truncating mutation plus copy-neutral LOH, the two exceptions (Table 1) being C70 (Figure 1(3A) ) and LS1034 (Figure 1(3B) ). In comparison, third hits were significantly more frequent (11/18, 61%; w 2 1 ¼ 5.8, P ¼ 0.016) in lines with truncating APC mutation(s) and no LOH. Importantly, polyploidy (P ¼ 0.24) and chromosomal instability (measured by the total genome-wide number of chromosome-scale gains or deletions of >10 Mb, P ¼ 0.38) were not independent predictors of a third hit when these variables were incorporated into a logistic regression model, whereas copy-neutral LOH remained a significant predictor (P ¼ 0.025).
Demonstration of three hits at APC in primary CRCs
To exclude our observations of three hits at APC being the result of phenomena that were restricted to cancer cell lines, we screened a panel of 70 primary sporadic CRCs for genetic changes at APC. In primary cancers that have not been rigorously microdissected, allelic imbalance (AI) and aCGH analyses cannot always detect and distinguish between true LOH, deviation in allelic ratios without true reduction to homozygosity, copy number change and unbalanced polyploidy (Figure 2) . We therefore reasoned that the existence of three hits could not readily be assessed in every primary cancer and that accurate assessment of the frequency of third hits was not possible in our primary CRCs. Our analysis was therefore restricted to showing that third hits were not a cell line artefact.
Using the criteria detailed in Figure 2 , we found 12 CRCs, both polyploid and near-diploid, with evidence of three hits at APC (Table 2) . Half of these CRCs had a single truncating APC mutation, a presumed (but Estimated number of copies gained or deleted is shown, relative to the overall level of ploidy. Our suggested mechanism to explain the observed changes is also shown. Note that (i) copy number is shown relative to the overall level of ploidy; third hits do not, therefore, result simply from the acquisition of the polyploid karyotype; (ii) no evidence of monoallelic expression without LOH-for example, as a result of methylation-related transcriptional silencing-was detected in any line; (iii) the following cell lines without evidence of third hits were analysed, but data are not shown in detail: CX1, HCA46, HT29, HT55, LOVO, SW403 and VACO5 (all two trunc. only); HCA7 and SKCO1 (both one trunc. only); C10, HCT15/DLD1, LIM1863, SW620, VACO4S, SW1222, CACO2 and COLO678 (all trunc.+LOH by MR); HRA19, COLO320, VACO10MS and T84 (all trunc.+LOH by whole chromosome loss and redup); C99, GP5D, C125PM and SW1417 (all trunc.+LOH by deletion); COLO741 (deletion, but no LOH); and H716, HCT116, HUTU80, LS174T, RKO, SNUC2B, SW1116 and SW48 (nil found).
APC and the three-hit hypothesis S Segditsas et al Figure 1 Third-hit genetic pathways involving APC. When analysing data on mutations, copy number changes and LOH at a locus such as APC, the correspondence between the biological phenomena and their detection using technically imperfect molecular methods must initially be borne in mind. Some illustrations are as follows. First, deletion in a diploid cell leads to true LOH (in the sense of molecular reduction to homozygosity), but deletion of one copy in a polyploid cell generally does not cause true LOH. Second, copy number gain does not lead to true LOH (unless artefactually if many copies of the same homologue are gained). Third, aneuploidy/polyploidy per se does not cause true LOH (except in the very rare haploid situation), although it often does cause allelic imbalance in primary cancers (see Figure 2) . Fourth, microsatellites (and other polymorphisms) measure LOH through relative allelic dosage, aCGH measures copy number relative to the DNA content of the tumour as a whole and FISH measures total copy number. The figure summarizes the pathways that most plausibly underlie most of the observed combinations of genetic changes at APC in the CRC cell lines, and that can be detected using the above analyses. The cancer cell's complement of changes at APC is shown, with a truncating mutation denoted by a cross, deletion by an open box and gain (of a mutant allele) by a black box. Copy-neutral LOH is shown, for convenience, as occurring by mitotic recombination. It is assumed that the 'third hits' occur after the cell has acquired a near-triploid karyotype, as most CRC cell lines are near-triploid; however, the principles of the three-hit analysis are extendable to other karyotypes. Note that in some cases, such as cells with two truncating APC mutations and deletion (1B), deletion must have occurred at the polyploid stage (for otherwise, there would be a single truncating mutation plus a deletion that causes LOH (2A or 2B)), but in other cases, such as gains of APC (1C, 3B) , that third hit could also have occurred in a near-diploid cell.
APC and the three-hit hypothesis S Segditsas et al undetected) second truncating mutation and deletion without AI (although it must be borne in mind that LOH analysis can occasionally produce false-negative errors and that some of these cancers may actually have had LOH as a second hit by deletion). It is therefore important to note that we identified other cancers with very good evidence of three hits, specifically: (i) two CRCs with two detectable truncating mutations and deletion; (ii) two cancers with third hits by copy number gain; (iii) a cancer that had acquired a truncating mutation, LOH of the whole chromosome by deletion, and then a further smaller deletion involving APC ( Figure 3a) ; and (iv) a CRC (no. 1015) that had acquired two protein-truncating mutations (at codons 216 and 1315), together with LOH at all three markers close to APC, but without copy number change. In this last case, Figure 2 Third-hit genetic pathways involving APC in primary cancers. The figure shows scenarios where third hits can reliably be detected in primary cancer specimens: (a) two truncating mutations and copy number deletion; or (b) one or two detected truncating mutations and copy number gain; (c) one detected truncating mutation and copy number deletion in the absence of AI; or (d) two truncating mutations and AI without copy number change in a near-diploid cancer.
the most parsimonious explanation was that an initial protein-truncating mutation was followed by copyneutral LOH and then by a further mutation on one of the two copies of chromosome 5 (Figure 1(3C) , Figure 2d ); given that mutations near APC codon 1309 are generally associated with LOH (Lamlum et al., 1999) , it is likely that the codon 1315 mutation was the first event, and that the codon 216 mutation proximal to codon 1315 provided an additional advantage by producing a more severely truncated protein.
Loss of a mutant APC allele in progression from adenoma to carcinoma
In general, copy number changes at APC are rare in colorectal adenomas and most of these lesions are neardiploid (Sieber et al., 2002; Jones et al., 2007) . It seems unlikely, therefore, that third hits are common in adenomas. During investigation of eight 'malignant polyps' (CRC with contiguous adenoma), we discovered an example of a third hit following laser capture microdissection of the two parts of the lesion (Figure 3b ). The adenomatous component did not show AI and contained an APC mutation at codon 1406 and a presumed cryptic second hit. In the cancer, there was near-complete AI. Both parts of the lesion contained a p53 E171X mutation, demonstrating a common origin. Thus, this lesion had lost an APC-mutant allele during progression from adenoma to carcinoma.
Do some third hits not only involve APC but also target it?
Some background copy number changes must inevitably occur in chromosomally unstable (CIN þ ) cancers and some of these may involve chromosome 5q. Alternatively, a locus other than APC on 5q might be specifically targeted by these changes. However, the detection of two protein-truncating APC mutations in cancer no. 1015 with LOH shows that APC can be the third-hit target. In addition, the following indirect evidence suggests that copy number third hits may also sometimes target APC: Do third hits at APC affect mRNA and protein levels? Given that most truncated APC proteins found in vivo retain some b-catenin-binding activity, it is possible that copy number changes modulate Wnt signalling by this means. Direct in vitro evidence for the functional consequences of third hits at APC is, however, extremely difficult to obtain, given that any effects are likely to be quantitative rather than qualitative, and there are severe problems in precisely replicating the in vivo situation in any artificial or model system. However, it is known that using siRNA or the expression of exogenous mutant Schneikert et al., 2007) . We determined whether the level of APC mRNA co-varied with total APC copy number using 24 of our CRC cell lines. APC expression was a median of 0.014 (inter-quartile range ¼ 0.004-0.039) of that of the per copy expression of the control GAPDH mRNA. Higher genomic APC copy number was significantly associated with increased APC mRNA expression (Spearman's t b ¼ 0.53, P ¼ 0.008). We then showed, using subclones of the SW837 cell line that differ in APC copy number, that this mRNA difference was proportionately reflected in protein levels (details not shown).
Discussion
The two hits at APC that initiate colorectal tumorigenesis are usually bi-allelic truncating mutations that occur at non-random positions with respect to each other. The resulting residual protein function produces a level of Wnt signalling that is close to the optimum (Lamlum et al., 1999; Albuquerque et al., 2002) . When true LOH (reduction to homozygosity) occurs at APC, it usually involves no copy number change (Sieber et al., 2002; Gaasenbeek et al., 2006) . This observation has produced an apparent paradox, in that in CRCs, copy number changes at APC are common. These copy number changes can take the form of gain or deletion in both near-diploid and aneuploid cancers. We have shown that the copy number changes are effectively third hits. Very occasionally, moreover, CRCs can acquire three hits without copy number change, for example by two somatic mutations plus copy-neutral LOH. Our data suggest that at least some of these third hits specifically target APC and can affect APC mRNA and protein levels. Our findings support a model whereby some CRCs respond to a changing environment by modulating Wnt signalling through copy number changes or other types of third hit at APC. We recognize that the accepted genetic model of colorectal tumorigenesis might be incorrect, in that APC inactivation is not the initiating event in the pathogenesis of some colorectal tumours, but might occur after the carcinoma has become polyploid, such that three or more hits are needed to inactivate the protein. This is contrary to the bulk of evidence from colorectal adenomas (Sieber et al., 2005; Jones et al., 2007) and cannot apply to third hits that occur by gain, by truncating mutation or in near-diploid tumours. It is not clear as to why third hits at APC only occur in some CRCs, or why some tumours have gains and others deletions. Perhaps different cellular environmentsincluding accumulated mutations-confer different selective constraints, leading to different selection pressures and hence different requirements for third hits. Cancers without third hits may have acquired alternative molecular changes that allow them to acquire a near-optimal level of Wnt signalling. An intriguing, but unexplained, observation is the paucity of third hits where the cancer's second hit is by copy-neutral LOH. We found no evidence to suggest that this association resulted from some secondary effect of chromosomal instability. One explanation might lie in the fact that copy-neutral LOH causes all APC mutations in the cell to be identical. Polyploidization does not, therefore, 'unbalance' the original two hits and third hits are not selected.
Three hits at APC have previously been shown to occur in tumours from patients with specific germline mutations that cause attenuated familial adenomatous polyposis (AFAP). In AFAP, these third hits often take the form of loss of a germline mutant allele or a mutation at codon 1554 in cis with a more proximal germline mutation (Spirio et al., 1998; Su et al., 2000; Sieber et al., 2006) . It is intriguing that some of our sporadic CRCs had changes compatible with the loss of a mutant allele and others had mutations at codon 1554, a change that is found quite rarely in tumours from patients with classical FAP. It is conceivable, therefore, that some codon 1554 (or similar) mutations in sporadic CRCs were unrecognized third hits.
In their influential review of carcinogenesis, Hanahan and Weinberg (2000) stated that tumours develop and progress through stepwise accumulation of mutations in different functional pathways. Our data suggest that repeated targeting of the same pathway and/or gene occurs in some cancers, perhaps to allow adaptation to changing genetic, cellular and tissue environments. Our data provide further evidence to suggest that APC does not follow the conventional TSG model in which two copies are simply inactivated. In the conventional model, all subsequent events in that tumour cell take place on a background of the loss of TSG function, and there is no realistic possibility of the TSG acquiring further mutations to alter its function. We tentatively suggest that, for APC, this 'multiple hit' model be substituted for the 'two-hit' model. Evidently, we do not currently know whether this notion applies to genes other than APC. There is evidence, for example, that gains on chromosome 12p preferentially occur in CRCs that acquired KRAS2 mutations when they were adenomas (Leslie et al., 2006) , and this might be a case of a mutant oncogene genotype tracking the selective landscape. Where third hits occur at TSGs, either the cancer might be dependent on the sequential genetic changes for its growth or it might merely be 'fine-tuning'. If the former were the case, there would be considerable therapeutic potential for disrupting carcinogenesis by targeting genes that rely on 'multiple hits because small environmental changes might cause the genotype to become sub-optimal.
Materials and methods
A panel of 47 CRC cell lines was derived from public sources and collaborators. DNA and mRNA were extracted from The breast and ovarian cancer data are derived from our unpublished work. Note the peak frequency of change at APC (112 Mb) in the two types of colorectal cancer, but no evidence of such a peak in the other cancer types despite chromosomal instability in many of these cancers. these samples using standard methods. A panel of 70 freshfrozen primary CRCs and paired normal tissue was also studied. These samples had been snap-frozen at surgery and each cancer was shown to contain >65% malignant cells by histological review. Formalin-fixed, paraffin-embedded (FFPE) material was also available from the same cancers. DNA was extracted from each sample and from paired normal tissue.
For copy number assessment, aCGH analysis was undertaken on 1-Mb density bacterial artificial chromosome (BAC) arrays as described (Fiegler et al., 2003) . We used the terms 'gain' and 'deletion' for aCGH (copy number) changes. For consistency, we also referred to the absence of a whole chromosome as 'deletion'. The determination of significant copy number changes was performed using the program DNAcopy (http://www.bioconductor.org/repository/ release1.5/package/html/DNAcopy.html).
For assessing 'true LOH'-that is, reduction to homozygosity-in cancer cell lines, DNAs were studied using the Affymetrix (Santa Clara, CA, USA) GeneChip Human Mapping 10K Xba131 single nucleotide polymorphism arrays according to the manufacturer's instructions. Median call rates of 96% (IQR ¼ 90-97%) were achieved. The MGCOS and GDAS (Affymetrix) software were used to process the output data according to the manufacturer's protocols and thresholds for scoring homozygotes and heterozygotes. Copy number change was not analysed using the Affymetrix system, since found aCGH to be more reliable and to provide better quantitation.
True LOH at APC could not readily be assessed in the primary cancers, owing to inevitable contaminating 'normal' cells that prevented differentiation between copy number changes that caused relative shifts in allelic dosage and true reduction to homozygosity. AI, a measure of nominally significant deviation from a 1:1 allelic ratio, was therefore assessed instead. We used microsatellite markers just distal to the APC locus (D5S346, D5S421 and D5S656) on the Applied Biosystems (Foster City, CA, USA) 3100 sequencer. Constitutionally, homozygous markers were scored as non-informative. At each marker, AI was considered present if the area under one allelic peak in the adenoma was less than 0.5 times or greater than 2 times that of the other allele, after correcting for the relative allelic areas using constitutional DNA. Although these somewhat arbitrary thresholds are commonly used to score AI/LOH, we had previously confirmed that they showed good performance (specificity of 86% and sensitivity of 68%) by finding (i) a bimodal distribution separating freshfrozen samples with LOH from those without, with a division at ratio o0.58 or >1.72; (ii) measurement of allelic ratios in a panel of normal DNA samples and cancer cell lines with various known copy numbers at APC; and (iii) use of the CRC cell lines to verify concordance between LOH as assessed by microsatellites with that assessed by SNP microarrays (OM Sieber et al., in preparation) . The ratios of 0.5 and 2.0 were used to err on the side of sensitivity rather than specificity and to provide consistency with previous studies. All tests were performed in duplicate, and in the infrequent event of discordance between markers, precedence was given to the marker closest to the APC gene.
The APC gene was screened for mutations proximal to the site of the first serine-alanine-methionine-proline (SAMP) repeat at codon 1580 using direct sequencing in forward and reverse orientations (details available on request). Any possible mutations were re-sequenced from a new PCR product. The bcatenin gene (exon 3) was sequenced similarly. Microsatellite instability was assessed using the markers BAT25 and BAT26. Bandshift at either of these mononucleotide repeats was taken as indicative of microsatellite instability þ status.
From selected CRC cell lines, we undertook full chromosome counts and karyotype analysis using standard methods. Fluorescence in situ hybridization was performed on selected cell lines by standard methods using an APC-specific BAC probe and a chromosome 5q paint was used in a similar manner (details available on request). For assignment of ploidy in the primary CRCs, we used flow cytometric analysis. All tumours with evidence of an aneuploid and/or polyploid flow cytometry peak, distinct from the diploid peak and corresponding to a DNA index of greater than 1.2, were classed as polyploid.
